Global aesthetics corporations JETEMA set a goal of achieving 100 billion won in annual sales this year.
The company said on the 8th that at a New Year's ceremony on the 2nd under the theme of "At the door of change," it shared the achievement of posting its best-ever results last year and unveiled a concrete roadmap to target the global market.
JETEMA expanded investment in research and development last year. It completed establishing a CGMP (U.S. current good manufacturing practice) system at its Wonju plant, dramatically boosting filler production capacity. Its flagship filler product "e.p.t.q" obtained approvals in about 80 countries worldwide.
The company selected "direct global push" and "work digitalization" as this year's core strategies. It plans to obtain additional approvals for "The Toxin" in Turkey, Thailand and the UAE, and accelerate entry into the Chinese and Brazilian markets. It said it will build a direct sales network in the United States, the largest market, successfully complete U.S. phase 3 clinical trials, and pursue global licensing-out (L/O, technology transfer).
It also plans to adopt artificial intelligence (AI) to automate repetitive tasks. The aim is to build a smart work environment that allows employees to focus on more creative and productive work.
JETEMA also expressed its ambition to usher in an era of 1 trillion won in sales within the next 10 years. A JETEMA official said, "The new slogan, 'Just Trust Me (JTM),' embodies a determination to leap forward boldly toward the world based on trust among management, employees and customers," adding, "2026 will be the true first year of JETEMA's rise as a global leader."